Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DEXYCU
- Development stage
- Unknown
- Lead developer
- EyePoint Pharmaceuticals
- Modality
- Small Molecules
- Administration
- Ophthalmic, Intracameral
01
Overview
DEXYCU (OT-502) is a sustained-release, 9% intraocular suspension of dexamethasone, a potent corticosteroid. It is specifically designed for the treatment of postoperative inflammation following cataract surgery. Originally developed by EyePoint Pharmaceuticals and licensed to Ocumension Therapeutics for the Greater China region, the drug is administered as a single intraocular injection into the posterior chamber or capsular bag at the conclusion of surgery. This delivery system provides a controlled release of dexamethasone for up to 22 days, effectively replacing the need for patient-administered steroid eye drops. Dexamethasone acts as an agonist of the glucocorticoid receptor, exerting anti-inflammatory and immunosuppressive effects by inhibiting the expression of various inflammatory mediators. While FDA-approved in the United States, Ocumension has completed Phase 3 trials and submitted a New Drug Application (NDA) in China.
- Brand names
- DEXYCU
- Other names
- dexamethasone intraocular suspension9% dexamethasone intraocular injectiondexamethasone intraocular suspension 9%
02
Targets
GR (Glucocorticoid receptor)
Beyond the preview
Go deeper on DEXYCU.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DEXYCU.